2.4
正电子发射断层扫描(PET)是一种医学影像技术,涉及放射性药物——即发出短暂辐射的物质。虽然第一台PET扫描仪于1961年问世,但直到15年后,放射性药物与这项技术进行结合,才革新了它的潜力。
PET扫描的一个主要要求是需要一个放射性的正电子放射性同位素,该同位素是在环型的加速器中产生的,然后与用于…
正电子发射断层扫描(positron emission tomography,PET)是一种基于放射性示踪剂的医学成像技术,常用于肿瘤检测、判断转移范围、评估心肌供血不足等心脏疾病,以及研究 大脑中的神经活动
进行PET扫描时,患者通常会被注射一种放射性示踪剂,该示踪剂是一种与正电子发射同位素(如碳-11、氧-15或氟-18)结合的生物分子。
进入体内后,这些放射性示踪剂会在其亲和力较高的组织或细胞内聚集。例如,氟脱氧葡萄糖(FDG)会因肿瘤具有较高的代谢活性而在肿瘤中大量聚集。
不稳定的放射性氟发生衰变,释放出正电子——即带正电荷的电子反粒子。正电子与附近的电子结合,发生湮灭反应,并向相反方向发射两个能量为511 keV的光子。
PET 探测器收集数百万次此类湮灭事件,并利用复杂的计算算法重建研究区域内示踪剂分布的图像。
View the full transcript and gain access to JoVE Core videos
Q1: What is positron emission tomography and what are its main clinical applications?
Positron emission tomography (PET) is a radiotracer-based medical imaging technique that detects positron-emitting isotopes to visualize tissue function. PET is widely used to diagnose tumor detection, determine cancer metastases, evaluate heart disease and impaired blood supply, study brain neural activity, and assess infections, bone disease, and thyroid conditions. Unlike static imaging, PET reveals physiologic activity including nutrient metabolism and blood flow.
Q2: How do radiotracers work in a PET scan?
Radiotracers are biological molecules bound to positron-emitting isotopes like fluorine-18 or carbon-11. When injected into the patient, they accumulate in tissues with higher affinity, such as tumors with elevated metabolic activity. For example, fluorodeoxyglucose (FDG) concentrates in cancer cells because they metabolize glucose differently than normal tissue, allowing PET to detect abnormal regions.
Q3: What happens during the positron annihilation process in PET imaging?
Radioactive fluorine decays and emits positrons, which are positively charged antiparticles of electrons. When positrons combine with nearby electrons, an annihilation reaction occurs, emitting two photons of 511 keV energy in opposite directions. PET detectors collect millions of these annihilation events and use complex computing algorithms to reconstruct detailed images of tracer distribution in the body.
Q4: How is a radiotracer prepared for use in PET scanning?
Positron-emitting radioisotopes are produced in a cyclotron through proton bombardment. For example, fluorine-18 is created by bombarding oxygen-18, then incorporated into a glucose analog called fludeoxyglucose (FDG). This tagged compound is then injected intravenously or inhaled as a gas, allowing the scanner to track how tissues utilize the radiotracer.
Q5: How does PET imaging differ from CT and MRI scans?
PET scans reveal physiologic activity, including nutrient metabolism and blood flow, showing how organs function. In contrast, computed tomography and magnetic resonance imaging produce static anatomical images. PET is now typically performed alongside computed tomography or magnetic resonance imaging to provide comprehensive data visualization and improve diagnostic interpretation.
Q6: What information can PET imaging reveal about brain function?
PET can locate regions in the brain that become active during specific activities such as speaking or closing the eyes. By tracking radiotracer accumulation in different brain areas, PET reveals neural activity patterns and can detect brain abnormalities. This functional imaging capability makes PET valuable for studying cognitive processes and diagnosing neurological conditions.
Q7: What are the advantages of using different radiotracers in PET imaging?
Different radiotracers target specific tissues based on their biological properties. For example, radioactive iodine monitors thyroid function, while radioactive gallium detects cancer. Fluorodeoxyglucose (FDG) reveals glucose metabolism differences between normal and abnormal tissues. This versatility allows PET to diagnose diverse conditions by selecting radiotracers that accumulate in the target organ or pathology.